Nalidixic acid by intravenous infusion. A report of 50 cases.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use; D002228:Carbenicillin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003091:Colistin / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009268:Nalidixic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy; D013449:Sulfonamides / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D014552:Urinary Tract Infections / Q000188:drug therapy*; D014556:Urine / Q000382:microbiology
D010406:Penicillins; D013449:Sulfonamides; D009268:Nalidixic Acid; D000667:Ampicillin; D013752:Tetracycline; D002228:Carbenicillin; D003091:Colistin